WINTON GROUP Ltd Invests $9.21 Million in Charles River Laboratories International, Inc. $CRL

WINTON GROUP Ltd bought a new position in Charles River Laboratories International, Inc. (NYSE:CRL) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 46,163 shares of the medical research company’s stock, valued at approximately $9,209,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Tema Etfs LLC bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth about $26,000. Rothschild Investment LLC increased its position in shares of Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after purchasing an additional 84 shares during the last quarter. Atlantic Union Bankshares Corp bought a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at about $31,000. Geneos Wealth Management Inc. grew its position in shares of Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after buying an additional 145 shares during the last quarter. Finally, Activest Wealth Management grew its position in shares of Charles River Laboratories International by 10,900.0% during the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after buying an additional 218 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Mizuho set a $192.00 price objective on shares of Charles River Laboratories International in a research report on Friday, May 8th. CLSA raised shares of Charles River Laboratories International from a “hold” rating to an “outperform” rating and boosted their price objective for the company from $167.00 to $219.00 in a research report on Friday, May 29th. TD Cowen lowered their price objective on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Monday, April 13th. Eleven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Charles River Laboratories International currently has an average rating of “Moderate Buy” and a consensus price target of $208.50.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $181.46 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The firm has a 50-day simple moving average of $171.37 and a 200 day simple moving average of $181.57. The company has a market cap of $8.74 billion, a PE ratio of -48.26, a P/E/G ratio of 2.12 and a beta of 1.46. Charles River Laboratories International, Inc. has a fifty-two week low of $143.06 and a fifty-two week high of $228.88.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. The firm had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. Charles River Laboratories International’s revenue was up 1.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.04 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.